News | 03 June 2022
GSK to form consumer healthcare business ‘Haleon’
The proposed demerger is the most significant corporate change for GSK in the last 20 years
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
As per partnership, Carbanio will arrange raw materials and other custom chemicals for Proexp Pharma Pvt. Ltd. through an uninterrupted digital process of the company
The site, located in Berkeley County, will be operated using the same quality standards as DuPont’s Healthcare Industries Materials Site, the company’s longstanding biopharmaceutical manufacturing site in Hemlock, Michigan
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
PAYBACK loyalty will be live in 4500 Apollo Pharmacy outlets across India
This agreement is in addition to the $92 million filling line expansion announced in November 2021
The product will be launched by NATCO's commercial partner Viatris.
New logo reflects Thyrocare’s transformation since 1996 to its current leading position at the cutting edge of Diagnostic services
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The integration and transition of the brands are expected to be completed by June 2022.
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Subscribe To Our Newsletter & Stay Updated
